Nigerian pharmaceutical companies saw their finance costs climb sharply in the first quarter of 2026, driven by the prevailing high interest rate environment.Industry data shows that the combined borrowing expenses of major local drugmakers rose by 47% year-on-year during the period.
The spike reflects the impact of tighter monetary policy and expensive credit facilities that many manufacturers rely on for operations and expansion.The increase has put pressure on profit margins across the sector.
With the cost of loans and working capital rising, many pharma firms are contending with higher production expenses at a time when input costs and foreign exchange pressures remain elevated.
To manage the situation, some companies are adjusting their strategies. Options being explored include renegotiating loan terms, cutting non-essential spending, and seeking alternative funding sources such as equity or partnerships.
Others are focusing on improving operational efficiency to offset the impact on profitability.Stakeholders say sustained high interest rates could slow investment in new drug lines and capacity expansion. They are calling for targeted support and more affordable financing windows to help local manufacturers remain competitive and keep essential medicines accessible to Nigerians.
